Among these there are the anti-MIF mAb inhibitor Bax69 that is in Phase I/II clinical trials for cancer patients, the anti-CD74 mAb milatuzumab that is approved for hematological malignancies, and the tautomerase inhibitor Ibudilast that is clinically used in bronchial asthma treatment and is being repurposed for immunoinflammatory conditions [7,20]. Here, CD74 is linked to hematologic disorder.